Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092037 · ClinicalTrials.gov registry record
Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics
A clinical trial of Contraception, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT03092037: Completed study of Contraception, sponsored by University of Colorado, Denver.
NCT03092037 is a study of Contraception that has completed, run by University of Colorado, Denver. The registered enrollment target is 900 participants, above the 442-participant average among 72 other Contraception trials with a reported enrollment target (104% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03092037, a study of Contraception, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study will investigate the relationship between genetic variants and serum contraceptive hormone levels, specifically the progestin etonogestrel. This study will provide the foundation for future pharmacogenomic investigations of more commonly used contraceptive methods with higher failure rates.
Primary Outcome
Genetic variants will be analyzed using a Taqman microarray chip for 120 pre-selected variants
Conditions Studied
Interventions
- PROCEDURE Blood draw
Study Locations (1)
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2017-03-23 |
| Est. Completion | 2022-04-29 |
What the finished NCT03092037 record still lists
NCT03092037 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 442-participant average among 72 other Contraception trials with a reported enrollment target (104% higher).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT03092037 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03092037 about?
NCT03092037 is a clinical study titled "Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics". The proposed study will investigate the relationship between genetic variants and serum contraceptive hormone levels, specifically the progestin etonogestrel. This study will provide the foundation for future pharmacogenomic investigations of more commonly used contraceptive methods with higher fail...
What is the current status of trial NCT03092037?
This trial is currently completed. The enrollment target is 900 participants. The study started on 2017-03-23. Estimated completion is 2022-04-29.
What conditions does trial NCT03092037 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT03092037?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT03092037?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03092037 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03092037's enrollment target sits among peer trials
900 15th of 72 higher than 58 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI